Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS Abuse Legislation: GPhA and PhRMA Set To Battle Again

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate bill would allow generic companies to bring civil suits against brand sponsors that use REMS requirements to avoid providing samples for testing.


Related Content

FDA Exploring Whether Public Shaming Can Stop REMS Abuses
Gottlieb Q&A: Confirmation Is Nearing, Will Complete Response Letters Finally Get Released?
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
21st Century Cures Revisions Tell FDA To Highlight ‘Patient Experience Data’
FDA Hiring Campaign Continues; Goal Is Addressing Pending ANDAs
If You Can't Beat 'Em … Hire 'Em? PhRMA Exec Is New GPhA CEO
REMS And Generics: GPhA Needs Legislation, Continues Education
PDUFA Negotiations: REMS Mud-Slinging, Supply Chain Compromising, GAIN Diminishing?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts